Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
Cell-based therapies are gaining momentum as promising treatments for rare neurological autoimmune diseases, including neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. The development of targeted cell therapies is hampered by the lack of ad...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/15/7925 |
| _version_ | 1797525594080018432 |
|---|---|
| author | Judith Derdelinckx Tatjana Reynders Inez Wens Nathalie Cools Barbara Willekens |
| author_facet | Judith Derdelinckx Tatjana Reynders Inez Wens Nathalie Cools Barbara Willekens |
| author_sort | Judith Derdelinckx |
| collection | DOAJ |
| description | Cell-based therapies are gaining momentum as promising treatments for rare neurological autoimmune diseases, including neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. The development of targeted cell therapies is hampered by the lack of adequate animal models that mirror the human disease. Most cell-based treatments, including HSCT, CAR-T cell, tolerogenic dendritic cell and mesenchymal stem cell treatment have entered early stage clinical trials or have been used as rescue treatment in treatment-refractory cases. The development of antigen-specific cell-based immunotherapies for autoimmune diseases is slowed down by the rarity of the diseases, the lack of surrogate outcomes and biomarkers that are able to predict long-term outcomes and/or therapy effectiveness as well as challenges in the manufacturing of cellular products. These challenges are likely to be overcome by future research. |
| first_indexed | 2024-03-10T09:15:08Z |
| format | Article |
| id | doaj.art-97f12bb6be3548d2b5031c2c39555bb6 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T09:15:08Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-97f12bb6be3548d2b5031c2c39555bb62023-11-22T05:40:33ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-012215792510.3390/ijms22157925Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGADJudith Derdelinckx0Tatjana Reynders1Inez Wens2Nathalie Cools3Barbara Willekens4Department of Neurology, Antwerp University Hospital, 2650 Edegem, BelgiumDepartment of Neurology, Antwerp University Hospital, 2650 Edegem, BelgiumLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, BelgiumLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, BelgiumDepartment of Neurology, Antwerp University Hospital, 2650 Edegem, BelgiumCell-based therapies are gaining momentum as promising treatments for rare neurological autoimmune diseases, including neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. The development of targeted cell therapies is hampered by the lack of adequate animal models that mirror the human disease. Most cell-based treatments, including HSCT, CAR-T cell, tolerogenic dendritic cell and mesenchymal stem cell treatment have entered early stage clinical trials or have been used as rescue treatment in treatment-refractory cases. The development of antigen-specific cell-based immunotherapies for autoimmune diseases is slowed down by the rarity of the diseases, the lack of surrogate outcomes and biomarkers that are able to predict long-term outcomes and/or therapy effectiveness as well as challenges in the manufacturing of cellular products. These challenges are likely to be overcome by future research.https://www.mdpi.com/1422-0067/22/15/7925NMOSDneuromyelitis optica spectrum disordersMOGADMOG antibody-associated diseasecell therapydendritic cell |
| spellingShingle | Judith Derdelinckx Tatjana Reynders Inez Wens Nathalie Cools Barbara Willekens Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD International Journal of Molecular Sciences NMOSD neuromyelitis optica spectrum disorders MOGAD MOG antibody-associated disease cell therapy dendritic cell |
| title | Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD |
| title_full | Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD |
| title_fullStr | Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD |
| title_full_unstemmed | Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD |
| title_short | Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD |
| title_sort | cells to the rescue emerging cell based treatment approaches for nmosd and mogad |
| topic | NMOSD neuromyelitis optica spectrum disorders MOGAD MOG antibody-associated disease cell therapy dendritic cell |
| url | https://www.mdpi.com/1422-0067/22/15/7925 |
| work_keys_str_mv | AT judithderdelinckx cellstotherescueemergingcellbasedtreatmentapproachesfornmosdandmogad AT tatjanareynders cellstotherescueemergingcellbasedtreatmentapproachesfornmosdandmogad AT inezwens cellstotherescueemergingcellbasedtreatmentapproachesfornmosdandmogad AT nathaliecools cellstotherescueemergingcellbasedtreatmentapproachesfornmosdandmogad AT barbarawillekens cellstotherescueemergingcellbasedtreatmentapproachesfornmosdandmogad |